ROIS CDMO, a subsidiary of ROVI Pharmaceuticals, is a contract development and manufacturing organisation (CDMO) that provides comprehensive services for the development and production of injectable drug products. With a focus on sterile and high-potent formulations, ROIS CDMO offers end-to-end solutions to pharmaceutical and biotechnology companies worldwide. The company has recently expanded its global footprint by acquiring a sterile injectable manufacturing facility in Phoenix, Arizona, from Bristol Myers Squibb. This acquisition enhances ROIS CDMO’s capabilities and positions it as a transatlantic CDMO with direct U.S. production capacity.

Key Products and Services:

Sterile Injectable Drug Products: Development and manufacturing of sterile injectable formulations, including pre-filled syringes and vials.

High-Potent and Cytotoxic Formulations: Expertise in handling and manufacturing high-potent and cytotoxic drug products.

Fill-Finish Services: Comprehensive fill-finish services for injectable drug products, ensuring quality and compliance.

Regulatory Support: Assistance with regulatory submissions and compliance to meet global standards.

Supply Chain Management: Integrated supply chain solutions to ensure timely and efficient delivery of drug products.

As a leading CDMO, ROIS CDMO is committed to providing high-quality, reliable, and efficient manufacturing solutions for injectable drug products. With its expanded global presence and expertise in sterile and high-potent formulations, the company is well-positioned to support the evolving needs of the pharmaceutical and biotechnology industries.